Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Application of losartan potassium and dacarbazine combined medicine to preparation of medicine for treating intestinal cancer

Inactive Publication Date: 2021-03-05
阿耳法猫(杭州)人工智能生物科技有限公司
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

There are no reports on the combined effects of losartan potassium and dacarbazine

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of losartan potassium and dacarbazine combined medicine to preparation of medicine for treating intestinal cancer
  • Application of losartan potassium and dacarbazine combined medicine to preparation of medicine for treating intestinal cancer
  • Application of losartan potassium and dacarbazine combined medicine to preparation of medicine for treating intestinal cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0023] Example 1 MTT method detects the sensitivity of different intestinal cancer cells to losartan potassium

[0024] 1. Experimental materials

[0025] (1) Drug: The chemical structural formula of losartan potassium is as follows:

[0026]

[0027] (2) Intestinal cancer cells: human intestinal cancer cells HCT116 and HT29 cells.

[0028] (3) Commercially available MTT kits.

[0029] 2. Experimental grouping

[0030] (1) Control group: blank control, that is, intestinal cancer cells were not treated with any drugs.

[0031] (2) Experimental group: intestinal cancer cells were treated with different concentrations of losartan potassium.

[0032] 3. MTT method to detect the sensitivity of different tumor cells to losartan potassium

[0033] (1) Inoculate human intestinal cancer cells HCT116 cells and HT29 cells into 96-well plates at the number of 5000-9000 cells per well. After the cells adhere to the wall, add PBS solutions of different concentrations of losartan pot...

Embodiment 2

[0035] Example 2 The effect of dacarbazine alone or the combination of losartan potassium and dacarbazine on the inhibition rate of intestinal cancer cells

[0036] 1. Experimental materials

[0037] (1) Drugs: losartan potassium, dacarbazine.

[0038] (2) Intestinal cancer cells: human intestinal cancer cells HCT116 and HT29 cells.

[0039] (3) Commercially available MTT kits.

[0040] 2. Experimental grouping

[0041] (1) Control group: intestinal cancer cells were only treated with dacarbazine.

[0042] (2) Experimental group: Different concentrations of losartan potassium and dacarbazine were used in combination to treat intestinal cancer cells.

[0043] 3. MTT method to detect the sensitivity of intestinal cancer cells to the combination of losartan potassium and dacarbazine

[0044] (1) Inoculate human intestinal cancer cells HCT116 cells and HT29 cells into 96-well plates at the number of 5000-9000 cells per well. After the cells adhere to the wall, add different r...

Embodiment 3

[0046] Example 3 The effect of dacarbazine alone or combined administration of losartan potassium and dacarbazine on the inhibition rate of human intestinal cancer tissue organoids

[0047] 1. Experimental materials

[0048] (1) Drugs: losartan potassium, dacarbazine.

[0049] (2) Intestinal cancer cells: Human intestinal cancer tissue organoids.

[0050] (3) Commercially available CellTiter-Glo 3D kit.

[0051] 2. Experimental grouping

[0052] (1) Control group: only treated with dacarbazine.

[0053] (2) Experimental group: Different concentrations of losartan potassium and dacarbazine were used in combination to treat human intestinal cancer tissue organoids.

[0054] 3. Sensitivity of human intestinal cancer tissue organoids to the combination of losartan potassium and dacarbazine

[0055] (1) Mix the treated human intestinal cancer cells with Matrigel Matrigel, add 50 μl of mixed Mtrigel Matrigel to each well on a 48-well plate, add 250 μl complete medium to each we...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the field of medicines, and particularly relates to an application of a losartan potassium and dacarbazine combined medicine to preparation of a medicine for treating intestinal cancer. The application of the losartan potassium and dacarbazine combined medicine to preparation of the medicine for treating intestinal cancer is proposed for the first time, losartan potassiumand the dacarbazine have an obvious synergistic effect, the curative effect is effectively improved, compared with a single component, for the losartan potassium and dacarbazine combined medicine, thecurative effect is more remarkable, and the lethality to tumor cells is improved. The dosage is effectively reduced, so that the toxic and side effects are reduced. The losartan potassium and dacarbazine combined medicine can also save cost, reduce economic burden of patients, provide a new approach for prevention and treatment of intestinal cancer, and have broad application prospects in the field of medicine and pharmacology.

Description

technical field [0001] The invention belongs to the field of medicine, and in particular relates to the application of losartan potassium and dacarbazine in the preparation of drugs for treating intestinal cancer. Background technique [0002] Colon cancer refers to cancers that occur in the intestinal tract, mainly colon cancer and rectal cancer, and is one of the most common malignant tumors in the world. Due to changes in people's living environment and living habits, the incidence of bowel cancer in my country has been increasing year by year in recent years. Colon cancer can spread to other tissues and organs through lymph, blood circulation and direct spread. There are no obvious symptoms in the early stage. When it is discovered, patients often miss the opportunity for surgical treatment and can only be treated with radiotherapy and chemotherapy. The side effects of drugs are very high, and the mortality rate of intestinal cancer is very high due to frequent postoper...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/655A61K31/4178A61P35/00A61P1/00
CPCA61K31/4178A61K31/655A61P1/00A61P35/00A61K2300/00
Inventor 李斌
Owner 阿耳法猫(杭州)人工智能生物科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com